70 results
8-K
EX-99.1
CDTX
Cidara Therapeutics, Inc.
13 Aug 24
Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
4:19pm
against both seasonal and pandemic strains of influenza with a single dose per flu season.”
Recent Corporate Highlights
Reacquired exclusive global
424B3
CDTX
Cidara Therapeutics, Inc.
31 Jul 24
Prospectus supplement
5:25pm
designed to deliver universal prevention and treatment of seasonal and pandemic influenza. We believe the reacquisition of CD388, along
8-K
EX-99.1
1gmp pe2l9vh3du66vx
15 May 24
Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
4:22pm
8-K
EX-99.1
m1k7 cpys6cdeczf
3 May 24
Other Events
8:00am
8-K/A
EX-2.1
e6i9asl911 rgzboy4
29 Apr 24
Entry into a Material Definitive Agreement
4:57pm
8-K
EX-99.1
nlrpni
6 Sep 23
Cidara Therapeutics Announces Janssen’s Election to Proceed Under its License Agreement Relating to Novel Drug-Fc Conjugates Targeting Influenza
8:05am
8-K
EX-99.1
frfct307 blm8ulk
11 May 23
Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
4:16pm
8-K
EX-99.1
x5y9qjhg0q vo
3 Nov 22
Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
5:30pm